🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Prospective Asian Multicenter Prostate Cancer Focal Therapy Study (ProAMFocal)

Recruitingn/aAges 40 Years - 85 YearsMaleSingapore General Hospital
NCT06491056 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This is a multicenter observational study of patients undergoing focal therapy for prostate cancer in Asia

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Prostate Adenocarcinoma * Maximum Gleason score 4+4 * Maximum cancer volume 1.5 ml (up to 2 lesions) or 3 ml (single lesion) * Maximum Prostate Specific Antigen (PSA) level 15 ng/dl * Maximum clinical stage T2c * American Society of Anesthesiologist Criteria 2 or less Exclusion Criteria: * Extra-prostatic Extension on multi parametric magnetic resonance imaging (mpMRI); capsular contact is permitted
💊

What it tests

  • Focal Therapy for Prostate Cancer
📍

Where

1 site
Singapore General Hospital
Singapore, Singapore
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy